Skip to main content
. 2021 Oct 4;10(22):2101370. doi: 10.1002/adhm.202101370

Figure 2.

Figure 2

MSR vaccine formulated with SARS‐CoV‐2 antigens attracts immune cells and sustainably releases vaccine adjuvants. a) Composition of SARS‐CoV‐2 MSR vaccine. Cumulative in vitro release of b) GM‐CSF (n = 3), c) MPLA (n = 2), and d) N, S1, and S2 antigens from MSRs (n = 3). Data represent mean ± SD. SEM images of e) unloaded MSRs before injection and f) SARS‐CoV‐2 MSR vaccine explanted 7 days after injection into the skin of BALB/c mice. Scalebar = 200µm and 20µm, respectively. g) Scaffold volume over time (n = 3). Data represent mean and SD.